We have detected that you are using Internet Explorer to visit this website. Internet Explorer is now being phased out by Microsoft. As a result, NHS Digital no longer supports any version of Internet Explorer for our web-based products, as it involves considerable extra effort and expense, which cannot be justified from public funds. Some features on this site will not work. You should use a modern browser such as Edge, Chrome, Firefox, or Safari. If you have difficulty installing or accessing a different browser, contact your IT support team.
COVID-19 – high risk shielded patient list identification methodology
Background
-
Solid organ transplant recipients who remain on long term immune suppression therapy.
-
People with specific cancers:
- people with cancer who are undergoing active chemotherapy or radical radiotherapy for lung cancer
- people with cancers of the blood or bone marrow such as leukaemia, lymphoma or myeloma who are at any stage of treatment
- people having immunotherapy or other continuing antibody treatments for cancer *
- people having other targeted cancer treatments which can affect the immune system, such as protein kinase inhibitors or PARP inhibitors *
- People who have had bone marrow or stem cell transplants in the last 6 months, or who are still taking immunosuppression drugs
-
People with severe respiratory conditions including all cystic fibrosis, severe asthma and severe COPD.
-
People with rare diseases and inborn errors of metabolism that significantly increase the risk of infections (such as SCID, homozygous sickle cell).
-
People on immunosuppression therapies sufficient to significantly increase risk of infection.*
-
People who are pregnant with significant congenital heart disease.
* entries marked with a star had some limitations in central data - see note below
Last edited: 2 March 2021 4:59 pm